Biofrontera Inc. to Report Third Quarter 2026 Financial Results on November 13, 2026
WOBURN, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S.-based biopharmaceutical company engaging in the development, manufacturing, and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy, today announced that it will report financial results for the third quarter ended September 30, 2026 before the market opens on Friday, November 13, 2026.
Management will host a conference call and webcast the same day at 10:00 a.m. Eastern Time to discuss the results and provide a business update.
Conference Call and Webcast Details
| Detail | Information |
| Date | Friday, November 13, 2026 |
| Time | 10:00 a.m. Eastern Time |
| U.S. / Canada toll-free | 1-877-877-1275 |
| International | 1-412-858-5202 |
| Webcast | https://event.choruscall.com/mediaframe/webcast.html?webcastid=pyDsmcVf |
Participants dialing in by telephone should ask to be joined into the Biofrontera call. The webcast will be accessible beginning approximately 20 minutes prior to the start of the call.
About Biofrontera Inc.
Biofrontera Inc. (NASDAQ: BFRI) is a U.S.-based biopharmaceutical company engaging in the development, manufacturing, and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company’s products, which include Ameluz® as well as the RhodoLED® Lamps are used for the treatment of actinic keratosis, a common skin condition characterized by the growth of pre-cancerous skin lesions and, following U.S. Food and Drug Administration approval in September 2026, superficial basal cell carcinoma. For more information, visit www.biofrontera-us.com.
Investor Contact
Ben Shamsian
Lytham Partners
shamsian@lythampartners.com
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for November
3 of the Best Dividend Stocks to Own
The 10 Best Companies to Invest in Now
These Overvalued Stocks Have Plenty of Room to Fall
United States